# An Efficacy and Safety Study of Sonazoid™ and SonoVue® in Participants With Focal Liver Lesions, Undergoing Pre- and Post-Contrast Ultrasound Imaging

> **NCT03335566** · PHASE3 · COMPLETED · sponsor: **GE Healthcare** · enrollment: 424 (actual)

## Conditions studied

- Liver Lesions

## Interventions

- **DRUG:** Sonazoid™
- **DRUG:** SonoVue®

## Key facts

- **NCT ID:** NCT03335566
- **Lead sponsor:** GE Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-11
- **Primary completion:** 2015-04-09
- **Final completion:** 2015-04-09
- **Target enrollment:** 424 (ACTUAL)
- **Last updated:** 2018-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03335566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03335566, "An Efficacy and Safety Study of Sonazoid™ and SonoVue® in Participants With Focal Liver Lesions, Undergoing Pre- and Post-Contrast Ultrasound Imaging". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03335566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*